Statistics

Total Visits

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)15

Select a period of time:

Number of views in the range

Views
Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)4

Views

Views
July 20242
August 20240
September 20241
October 20240
November 20241
December 20240
January 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States2
Canada1
United Kingdom1
 

Top cities views

Views
Chicago1
Ottawa1